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Abstract 
Within the field of liver transplantation the concepts of warm liver transplants and hepatocyte 
transplantation are currently under investigation. Although such novel research efforts are intricate 
and complex, the concept of human liver transplantation posed quite a challenge itself in the not so 
distant past. The development of the orthotopic liver transplant relied on numerous individuals and 
novel approaches of the time. Success resulted following cumulative developments in early 
experiments when Thomas Earl Starzl performed the first human liver transplantation 50 years ago 
in 1963. This article highlights key developments in the lead up to such an attempt, details of the 
procedure itself and biographies of three key leaders; Alexis Carrel, Peter Medawar, and Thomas 
Starzl. 
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Liver transplantation in the 21st 
Century 
 
Orthotopic liver transplantation (OLT) 
(see Box 1) is currently the only curative 
treatment for patients with end-stage liver 
failure. Although quality and length of life 
can be improved, patients are committed to 
lifelong immunosuppressant therapy. This 
carries its own risks in addition to those 
associated with the procedure.   
 
In the UK, at the end of March 2012, 553 of 
7,636 patients on the active transplant list 
were in need of a new liver.1 A 25% increase 
in liver-related deaths were reported 
between 2001 and 2009, where a male 
predominance was seen and the majority of 
cases occurred in those under 70 years old.2 
This signifies both the increasing burden on 
the NHS and the importance of OLT. As 
with many areas of organ transplantation, 
the demand far exceeds supply. 819 patients 
were removed from the total active waiting 
list during the financial year due to clinical 
deterioration and 508 died while waiting for 
a transplant.1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although transplant research has an 
extensive history, liver transplant 
developments span over a much shorter 
period. The year 2013 signifies an important 
landmark in liver transplantation with the 
first human OLT taking place 50 years ago. 
The general principles discovered in the 
build-up to such a success are discussed 
within this article and many of the basic 
concepts can be applied across 
transplantation medicine. Although 
significant developments have been made 
over that time, problems with organ supply 
still need to be tackled; techniques need to 
be refined and new technologies researched. 
The recent use of ‘warm liver’ transplants by 
the University of Oxford has proved 
successful, and novel approaches such as 
hepatocyte transplantations are currently 
under investigation.4,5  
 
The history of liver transplantation (see 
Figure 1) is an expansive topic; the purpose 
of this article is to focus on the key 
developments that led to the first human 
liver transplant. 
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Box 1. Key terms within transplantation3 
Orthotopic graft: tissue or organ transplant is placed in the same anatomical site as the 
original organ or tissue (e.g. heart or liver transplant) 
Heterotopic graft: tissue or organ transplant is placed within a different anatomical site (e.g. 
kidney transplant) 
Allograft (homograft): tissue or organ transplanted between genetically non-identical 
individuals of the same species (e.g. heart or liver transplants) 
Autograft: tissue or organ transplanted between different sites of the same individual (e.g. skin 
transplants) 
Heterograft (xenograft): tissue or organ transplanted from a different species (e.g. pig to 
human) 
Isograft (syngraft): tissue or organ transplanted between genetically identical individuals 
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Figure 1. Key pioneers6-8, Nobel Prizes (1901 – 1960) relating to immunology and transplantation9, and 
significant developments in liver transplantation history (pre-1963). 6-MP: 6-mercaptopurine, TBI: total 
body irradiation. Alexis Carrel and Peter Medawar images courtesy of the Wellcome Library, London. 
Thomas Starzl image courtesy of the Archives Service Center, University of Pittsburgh. 
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Alexis Carrel (1873-1944) Lyon, France 
 Major in the French Army Medical Corp 
(1914-1919) where he developed new 
methods to treat war wounds 
 Key developments include methods for 
blood vessel anastomoses (1902), whole 
organ transplantation (1908), and effective 
cold storage of blood vessels (1910). 
 He was the youngest Nobel Laureate age 39 
 
Peter Medawar (1915-1987) Rio de Janeiro, 
Brazil 
 Early work focussed on regeneration of 
peripheral nerves, tissue culture and 
development of organisms 
 Investigated skin grafts following requests 
from the Medical Research Council during 
the Second World War (1939-1945) 
 Once elected fellow of the Royal Society, 
London, he was then awarded a Royal 
Medal (1959) and Nobel Prize (1960) 
 
Thomas Earl Starzl (1926-), Iowa 
 Post-graduate surgical training focussed on 
vascular, thoracic and general surgery 
 Extensive research in organ transplantation 
with over 1600 publications 
 Performed the first human liver transplant 
(1963) 
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Transplant immunology 
 
Transplant immunology: blood 
reactions 
 
Karl Landsteiner, an assistant within the 
Pathological-Anatomical Institute in Vienna, 
was the first to discover blood groups in 
1900 following agglutination reactions, 
whereby antibodies and red blood cells, or 
corpuscles, adhere to form a mass, in normal 
human serum.10 Originally believed to only 
occur in diseased states, the reaction was 
later found in 22 healthy individuals, which 
categorized individuals into blood groups A, 
B or C.10 The possibility of successful blood 
transfusions became a reality. Identification 
of these blood groups was one of the first 
key steps in transplantation: correct 
identification and matching of individuals 
based on their blood group is a necessity in 
transplantations to prevent the agglutination 
process that could result in transplant 
failure. 
 
Transplant immunology: the mid- 
20th century 
 
Following on from Landsteiner, Medawar 
found, while working for the Medical 
Research Council in the 1940s, tissue 
reactions when using skin grafts.11 Skin 
homografts from the patient’s brother were 
used in a 22 year old woman with extensive 
burns. Subsequent biopsy specimens during 
each dressing change allowed the 
determination of local reactions within 
the tissues.11 At day five, both sets of grafts 
were similar to the naked eye and 
histologically.11 A subsequent polymorph 
and lymphocyte infiltration of collagen, and 
a multinucleate giant cell reaction, were 
seen.11 By day fifteen retrogressive changes 
had been shown, involving both a 
mesenchymal and vascular reaction, with a 
thin detached band of skin now replacing 
the previously well-grown tissue.11 Medawar 
reported the destruction of foreign tissue as 
the result of an antigen-antibody reaction.11 
In 1949 Burnet also showed how, when 
exposed to foreign antigens, antibodies were 
produced and further work developed the 
concept of cellular immunity.12 The immune 
system would target foreign body cells and 
cause destruction of tissue. Whether it was 
immediate or within weeks, the 
transplantation of organs between non-
identical humans would eventually resulted 
in rejection. A second culprit for the 
rejection reaction was identified. Compatible 
blood groups and tissue matching, a much 
more intricate task, were necessities for 
transplantation. Even so, a lack of control 
over the immune system was responsible for 
many of the earlier failures.  
 
Transplant immunology: early findings 
of tissue rejection 
 
The immune system needed to be 
suppressed after transplantation, and interest 
built in the use of cortisone and total body 
irradiation in an attempt to dampen down 
the immune response.  
 
In 1951, Billingham’s work with skin 
homografts and autografts in rabbits showed 
a role for cortisone in preventing transplant 
rejection.13 The transplanted tissues became 
swollen and hard, with a colour change to 
brick red and subsequently to what is 
described as “shades of dirty yellow, green 
or brown”.13 The tissue eventually degraded. 
Interestingly, following administration of 
cortisone it was reported that the usual acute 
progressive rejection, comprising of an 
inflammatory response, oedematous swelling  
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and lymphocytic infiltration, was converted 
to a chronic delayed reaction with 
intermittent progress.13 Cortisone extended 
the life of the homograft, with the belief that 
it either reduces the ability of the graft to 
elicit a response or by causing a direct 
dampening of the response itself.13 
 
Around the same time, kidney transplants 
were also being tested. Donor kidneys were 
being used from those who had succumbed 
to the guillotine and, although urine 
production was observed initially, the end 
result was unsuccessful in unmodified 
recipients.12 It would be three more years 
until a live donor kidney transplant took 
place between a mother and son. A mere 
three week survival of the graft was seen in 
another unmodified recipient.12 
 
Transplant immunology: dampening 
down the immune response 
 
As irradiation had already been proven 
effective at suppressing antibody production 
towards bacteria, Dempster wanted to apply 
irradiation to transplantation, reporting his 
experiments in 1950.14 Skin homografts in 
rabbits were utilized and irradiation was 
given at an average dose of 250 roentgens, 
resulting in prolonged survival of the 
grafts.14 Although successful at dampening 
the immune response, the species used were 
resistant to irradiation of this type.14 It was 
believed such a therapy was inapplicable to 
humans, but the fact remained that the 
rejection reaction was modifiable. Further 
work was required to develop more 
appropriate techniques to tackle the immune 
system. 
 
Significant findings in transplant 
immunology, such as tolerance in mice with 
immature immune systems, were later 
discovered by the Bilingham-Brent-Medawar 
experiments.12 Attention moved towards 
bone marrow and a form of tolerance was 
identified if recipients also had donor 
leukocytes in circulation. Nevertheless, 
unless tissues are closely matched, 
immunocompetent donor leukocytes hold 
the potential to lead to a graft-versus-host 
disease. 
 
Transplant immunology: genetic 
makeup 
 
A key landmark, and one of the first real 
successes of the time, came when Dr Joseph 
Murray and his team transplanted a kidney 
between identical twin brothers in 1954.15 
Prior to this, unsuccessful attempts had been 
made in Russia and the United States of 
America using both canines and humans.15 
Although the grafts initially showed success 
with urine output, urine production 
eventually ceased following a period of 
haematuria.15 At the time, 9 kidney 
transplants had been attempted by Murray’s 
group. Four showed significant renal 
function, with one showing clinical 
improvement for 5 months.15 All were 
eventually unsuccessful. It had already been 
shown that skin grafts between identical 
twins lacked the rejection reaction. Through 
reciprocal skin grafting, the two individuals 
under question were identified as identical.15 
The need for kidney transplantation 
followed a history of chronic 
glomerulonephritis in one twin with 
cardiomegaly, raised blood pressure and 
oedema.15 Following the procedure these 
normalised but, after discharge, urine 
showed casts and blood pressure rose.15 
Removal of diseased kidneys eradicated 
these problems and the graft was successful 
for 25 years.12 Key problems in kidney 
transplantation seemed to revolve around 
blood grouping, immune responses and 
disease status of the organ.15 Elective donors 
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over cadavers and intra-abdominal 
placement of the kidney were preferred.15 
The group also report infection playing a 
significant role in the destruction of donor 
tissue.15 
 
Transplant immunology: back to 
irradiation 
 
Although already identified as a potentially 
harmful modality, total body irradiation was 
finally applied to humans in 1962 where 
Murray et al. described experiences with the 
use of both chemical immunosuppression 
and irradiation.16 Out of twelve selected for 
total body irradiation (TBI) only one 
survived: a patient who received a kidney 
from a dizygotic twin.16 Murray also notes a 
total of 27 failed transplants using 
irradiation.16 With regards to chemical 
immunosuppression, thiopurine and 
actinomycin C were under investigation and, 
although 5 of 6 developed measurable renal 
function, only 1 survived over 120 days.16 
Research was moving away from radiation 
and moving towards new pharmaceutical 
developments. 
 
Transplant immunology: novel 
components 
 
With developments in chemical 
immunosuppression, thoughts focused on 
an antimetabolite, 6-mercaptopurine (6-MP). 
Success had been found in reducing 
antibody response in rats and so Schwartz in 
1959 carried out experiments on rabbits, 
again making use of homografts.17 4 groups 
were treated with 6-MP at varying doses for 
similar time periods. Mean rejection time 
increased in correlation with higher 6-MP 
doses and, although similar doses were used 
between one of the subcutaneous and oral 
groups, the oral route was found to be less 
effective at prolonging rejection time.17 
Following the initial homografts, the rabbits 
were given second homografts and a 
uniform accelerated rejection was seen.17 
Chemical immunosuppression alone had 
proved to be effective. 
 
Combinations of drugs were then used by 
Thomas Earl Starzl in 1963.18 He 
experimented with the use of prednisone in 
addition to azathioprine in human renal 
transplantation. Azathioprine, a derivative of 
6-mercaptopurine, was the mainstay 
treatment prior to the operation and was 
continued in all cases unless agranulocytosis 
persisted.18 At the time of rejection doses 
were increased with the hope of preventing 
the process. If unsuccessful, prednisone, 
150-400mg daily, was used secondarily as an 
antirejection therapy.18 The spleen and 
thyroid were removed in the majority of 
cases and intravenous actinomycin C 
administered during a rejection crisis.18 The 
combination was found to be successful at 
reversing rejection crises and preventing 
secondary rejection attempts.18 It had been 
shown that individuals tolerated grafts in the 
setting of chemical immunosuppression. 
 
Technical aspects to 
transplantation 
 
In the 19th century it had been impossible to 
repair blood vessels and early experiments 
with other organs had failed. Transplanting 
the liver, a complex organ with a dual blood 
supply, posed quite a challenge and technical 
advances were needed. Research focused 
mainly on the skin and kidney in subhuman 
species, ranging from rats and rabbits to 
canines. A major challenge of the time was 
tissue rejection; regarding both blood groups 
and tissue matching. 
 
H
IS
T
O
R
IC
A
L
 
 
 H
IS
T
O
R
IC
A
L
 
 
72 
                       Orthotopic liver transplantation in the making: key pioneers and events relevant to current practice               
Volume 21, Issue 1                                                                                                                     Res Medica  
 
70 
Basic technical aspects: blood vessel 
repair 
 
Aside from identifying and tackling 
problems of tissue rejection, the challenging 
technical components to transplantation  
also needed to be considered. At the time, 
tissues could be repaired but there were no 
means to successfully transfer organs within 
an individual, let alone between individuals. 
At the start of the 20th century research 
focused on surgical techniques and 
continued to make use of subhuman 
species.12 Alexis Carrel’s work in 1902 
opened the door to organ transplantation.9 
He aimed to refine anastomosis techniques 
in order to allow for blood vessels to be 
repaired just like other tissues were at the 
time. This is essential for transplantation as 
without adequate blood supply the graft will 
fail with necrosis of the involved tissues. 
 
Carrel believed by improving techniques, 
lives such as that of the French president 
Sadi Carnot, stabbed in 1894, could be 
saved.9 Using finer needles, developing the 
triangular method of anastomosis and 
demonstrating, with the help of Charles 
Guthrie, that veins could be used as arteries 
gave promise to the idea of transplantation.9 
Carrel successfully transplanted a dog’s 
kidney to its neck from its abdomen in 
1902.9 
 
Technical aspects: the build-up to the 
orthotopic liver transplant 
 
An effective procedure for the placement of 
axillary whole livers with results of around 
twelve days survival had been shown by 
Moore and Welch between 1955-1959.19,20 
Starzl used this approach in his own 
experiments with canine species and found 
an improved mortality rate.21,22,23 Technical 
failures were likely, and prolonged survival 
with the use of azathioprine, along with its 
hepatotoxic effects, were reported.23 It had 
become evident that vascularization was key 
in survival of grafts. Damage to the 
vasculature needed to be avoided as did any 
potential ischaemic damage to donor organs. 
Hypothermia, within the range of 10-20˚C, 
protected the liver for a short period, but 
prolonged ischaemia eventually resulted in 
liver injury.21 Similarly, excessive venous 
flow was also reported as damaging, 
resulting in congestion.21 The longest 
survival seen with this early work was 20.5 
days. Multi-organ transplants were also 
considered as fewer vascular anastomoses 
are required but success rates were low.22 
Congestion and haemorrhage were reported 
as the leading causes of death.22 
 
Following breakthroughs with anti-rejection 
therapy and the development of a successful 
transplant technique in canines, the 
opportunity arose for attempts in humans. 
Starzl set the stage for the orthotopic 
technique used today with the world’s first 
human liver graft in 1963.24  
 
Orthotopic liver transplant: the 
procedure 
 
At the time, successful liver transplantation 
would allow a major leap forward in the 
treatment of primary hepatoma, congenital 
atresia of the biliary system and terminal 
cirrhosis, for example.24 Details of the 
procedure, many of which remain today, can 
be found in Starzl’s original article.24 
 
One key step within Starzl’s procedure was 
the use of hypothermic perfusion. Early 
research had shown variable tissue sensitivity 
to anoxia which, if prolonged, could result in 
irreversible cellular injury. As of such Starzl 
used 5% dextrose, penicillin, heparin and 
 
H
IS
T
O
R
IC
A
L
 
 
73 
Gouldthorpe C.                                                                                              http://journals.ed.ac.uk/resmedica                                                                
 
Volume 21, Issue 1                                                                                                                                     Res Medica  
                                                                                                                                                                 
     
procaine hydrochloride, precooled to 15˚C 
to perfuse the donor liver in Starzl’s 
transplant. The donor body was also initially 
cooled to 15 ˚C, but increased to 20˚C 
between 45 and 104 minutes later. With 
hypothermic perfusion the aim was to keep 
the donor liver viable for as long as possible 
yet previous work had shown hepatocellular 
injury results if such perfusion persists for 
more than 2 hours.    
 
Although the operation was a success for 
two of the three subjects, survival was 
limited to 7.5 and 22 days. A number of 
problems were noted. The health of the 
donor organ was paramount; damage may 
lead to failure of the transplant and 
hypothermic perfusion for over 2 hours was 
detrimental. During the operation, increased 
fibrinolytic activity was noted close to the 
time of manipulation and removal of the 
liver, causing a bleeding diathesis in the first 
patient, and a hypercoagulable state 
followed, with pulmonary emboli present in 
the final two patients on autopsy. The need 
for improved coagulation control was 
documented.24  
 
From vessel repair to human 
liver transplants 
 
With further refinement of the technique 
and drug development, the procedure 
became more successful and at present 86% 
of transplanted livers in the UK function 
well within the first year.25 Initial work by 
both Landsteiner and Medawar brought to 
light the importance of the immune system 
in causing tissue reactions, and ultimately the 
cause of transplant failure that was seen 
throughout early experiments. Dating back 
as far as 1902, without Carrel’s work on 
vascular anastomoses Starzl’s work would 
have been unapproachable. The use of 
subhuman species, specifically canines, built 
the technical success which made Starzl’s 
procedure possible. With regards to current 
practice, knowledge can be gained even 
from the earliest attempts at OLT with the 
use of hypothermic perfusion and improved 
coagulation control, for example. 
Understanding the history of OLT and the 
challenges that have been overcome 
identifies not only important concepts which 
have been established but also the pitfalls 
that can be prevented in future use. 
Forgotten advances may even shed light on 
future conundrums within transplantation 
and other specialties. Although the history 
of liver transplantation is not made up 
wholly of Nobel Laureates, a vast number of 
pioneers from very different background 
played key roles in the gradual advancements 
which have resulted in success of the once 
questioned idea, and without them the lives 
of many would have been lost. 
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Key Learning Points 
 Prevalence rates and the demand for liver 
transplantation is rising 
 The development of the orthotopic liver 
transplant relied on numerous individuals 
and novel approaches of the time. 
Success resulted following cumulative 
developments. 
 Chemical immunosuppression is the 
mainstay treatment to control the 
immune system in liver transplantation 
but alternative approaches exist and may 
be of use if future challenges arise. 
 Although key elements in the pre-1963 
history of the orthotopic liver 
transplantation have been noted, the 
topic is extensive and numerous advances 
have been made in the past 50 years. 
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